Linsitinib (OSI-906)

Catalog No.S1091

Linsitinib (OSI-906) Chemical Structure

Molecular Weight(MW): 421.49

Linsitinib (OSI-906) is a selective inhibitor of IGF-1R with IC50 of 35 nM in cell-free assays; modestly potent to InsR with IC50 of 75 nM, and no activity towards Abl, ALK, BTK, EGFR, FGFR1/2, PKA etc. Phase 3.

Size Price Stock Quantity  
In DMSO USD 190 In stock
USD 170 In stock
USD 270 In stock
USD 720 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

4 Customer Reviews

  • Cancer Res 2013 73, 834-843. Linsitinib (OSI-906) purchased from Selleck.

    OSI-906 prevents the emergence and inhibits growth of established hormone-indendent tumors . A and B, MCF-7 cells were injected s.c. into athymic mice supplemented with 14-day release E2 pellets. Mice with no tumors (A) or bearing tumors ≥ 150 mm3 (B) were randomized to vehicle or OSI-906 (50 mg/kg/day, per os) for 6 weeks. Data are presented as number of tumors formed ; , P = 0.02, Fisher's exact test (A) , or mean tumor volume ± SEM; P < 0.05 versus vehicle, 2-way ANOVA (B). C, tumor-bearing mice from (A) were treated with vehicle or OSI-906 for 3 days. Xenografts were harvested 4 hours after the last dose. Tumor lysates were precipitated with a p-Tyr antibody; p-Tyr pull- downs and tumor lysates were analyzed by immunoblot with the indicated antibodies. D, tumor-bearing mice were imaged before and 4 hours after the initial dose of OSI- 906 by [18 F]FDG -PET. Images from a representative mouse show [18 F]FDG uptake pre- and post–OSI-906 (T-tumor ). Quantification is shown at the bottom.  , P < 0.0001, 2-way ANOVA .

    Cancer Res 2011 71, 6773-84. Linsitinib (OSI-906) purchased from Selleck.

  • (A) MHM cells were treated with CP (10 μM) alone or in combination with OSI-906 (5 μM) or Erlotinib (10 μM) for 48 hours and lysates were immunoblotted with indicated antibodies. EGFR immuno-precipitates were probed with anti-phospho tyrosine antibody. In lanes marked “Serum Starved”, MHM cells were serum starved for 24 hours and stimulated with EGF (10 ng/ml) for 10 minutes. Lysates were collected and immunoblotted with indicated antibodies. (B) OS cell lines and primary OS cells were treated with CP (10 μM) alone, OSI-906 (5 μM) alone or with CP in combination with OSI-906 for 48 hours and whole cell lysates were immunoblotted with the indicated antibodies. (C) MHM and S4 (CP resistant MHM derivatives) cells were treated with CP (10 μM) alone or in combination with OSI-906 (5 μM) for 48 hours and lysates were immunoblotted with indicated antibodies. (D) IGF1 and IGF2 mRNA levels in untreated cells and cells treated with 10 μM CP for 48 hours were determined by qRT-PCR. The level of each mRNA transcript in untreated cells was considered “1.0” and all the other values were plotted relative to it. Shown are the mean results of three experiments, bars, Standard error (SE).

    Oncotarget, 2016, 7(19):27511-26. Linsitinib (OSI-906) purchased from Selleck.

     

    (A) CLL B cells purified from freshly isolat ed or freeze-thawed PBMCs from CLL patient samples were treated with a single dose of 15 µM AG1024, 1µM PPP or 1µM linsitinib for 24h and cell survival was determined by flow cytometry. Results are shown as mean  ± SEM, n=20. (B)CLL B cells purified from freshly isolat ed or freeze-thawed PBMCs from CLL patient samples were treated with a single dose of 15 µM AG1024 (AG) or 1µM linsitinib (L) and immunoblotted for the expression of phosphorylated IGF1R and IRS-1 (n=6). (C) CLL B cells purified from freshly isolat ed or freeze-thawed PBMCs from CLL patient samples were treated with a single dose of 1µM PPP and immunoblotted for the expression of phosphorylated IGF1R and IRS-1 (n=4). (D) CLL B cells purified from freshly isolated or freeze-thawed PBMCs from CLL patient samples were treated with 5-15 µM AG1024 and subject to a Western blot analysis using the indicated antibodies. Results are represented as mean±SEM (n=10). Supplementary Figure 1C shows the associated densitometrical analysis after treatment with 15 µM AG1024. (E) CLL B cells purified from freshly isolat ed or freeze-thawed PBMCs from CLL patient samples were treated with 10-500nM rhIGF-1 and immunoblotted for the expression of IGF1R, pIGF1R, pAkt, Akt, pERK and Erk. A representative example from four independent experiments is shown.

    Linsitinib (OSI-906) purchased from Selleck.

Purity & Quality Control

Choose Selective IGF-1R Inhibitors

Biological Activity

Description Linsitinib (OSI-906) is a selective inhibitor of IGF-1R with IC50 of 35 nM in cell-free assays; modestly potent to InsR with IC50 of 75 nM, and no activity towards Abl, ALK, BTK, EGFR, FGFR1/2, PKA etc. Phase 3.
Targets
IGF-1R [1]
(Cell-free assay)
Insulin Receptor [1]
(Cell-free assay)
IRR [1]
(Cell-free assay)
35 nM 75 nM 75 nM
In vitro

OSI-906 inhibits IGF-1R autophosphorylation and activation of the downstream signaling proteins Akt, ERK1/2 and S6 kinase with IC50 of 0.028 to 0.13 μM. OSI-906 enables an intermediate conformation of the target protein through interactions with the C-helix. OSI-906 displays favorable metabolic stability in liver microsomes. OSI-906 fully inhibits both IR and IGF-1R phosphorylation at a concentration of 1 μM. OSI-906 inhibits proliferation of several tumor cell lines including non-small-cell lung cancer and colorectal cancer (CRC) tumor cell line with EC50 of 0.021 to 0.810 μM. [1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
A4-Fuk MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVTJR|UxRTBwMEK4NFYh|ryP M2P4cnNCVkeHUh?=
KS-1 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGL6UVBKSzVyPUCuNFM5OzVizszN M2XMb3NCVkeHUh?=
TE-11 NV3vPW02T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYLJR|UxRTBwMEe4NlIh|ryP MkPLV2FPT0WU
EW-1 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnjSTWM2OD1yLkC4OVg2KM7:TR?= MnzIV2FPT0WU
HMV-II NVXUSZRDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFjVTYZKSzVyPUCuNFg5PDZizszN NV;HXFFLW0GQR1XS
COLO-205 NIjTOGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFv1Om5KSzVyPUCuNVA1PTRizszN NE\4N5lUSU6JRWK=
ES1 NYHNVXNxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWnJR|UxRTBwMUC2PVYh|ryP NFG5ZotUSU6JRWK=
GDM-1 NH7HPYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1W1d2lEPTB;MD6xN|Y4OiEQvF2= NH\QXYJUSU6JRWK=
ML-2 NV3De3FiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWfsNG1KUUN3ME2wMlE2QDl4IN88US=> NHewPYRUSU6JRWK=
Saos-2 Mn\3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{SzVmlEPTB;MD6xOlUzPiEQvF2= M{HpeHNCVkeHUh?=
NCI-H1355 Mo\SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{DHWWlEPTB;MD6xPFE{PSEQvF2= M2G1eHNCVkeHUh?=
G-401 NYrVfG4zT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVrJR|UxRTBwMUiyN{DPxE1? M4fPVnNCVkeHUh?=
EW-16 NW\IdYFLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHzISJVKSzVyPUCuNVg4PzdizszN MVXTRW5ITVJ?
EW-7 NVTVPIlXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWHjOY1FUUN3ME2wMlE5QDhzIN88US=> M{PDNnNCVkeHUh?=
NCI-H727 NF\aOodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGHZT49KSzVyPUCuNVk4QTRizszN NHmxXG5USU6JRWK=
LCLC-97TM1 MkGwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWXJR|UxRTBwMkC5OVUh|ryP MX7TRW5ITVJ?
NCI-H650 M3nWb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGTx[VFKSzVyPUCuNlE{QDRizszN NFK4b4hUSU6JRWK=
NCI-H2122 MnfjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV7YWYNMUUN3ME2wMlI{Ojl7IN88US=> NX3vRm5NW0GQR1XS
SK-N-DZ NWDuU5RpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NISwfJJKSzVyPUCuNlM3QThizszN MmPrV2FPT0WU
HT-29 M1fsNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlHMTWM2OD1yLkK0NlQ5KM7:TR?= MWHTRW5ITVJ?
LB771-HNC MnezS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWTJR|UxRTBwMkW5NVUh|ryP M{TO[nNCVkeHUh?=
HT-144 NWDMNYk3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIHtfHVKSzVyPUCuNlYyQTFizszN NGrjTYpUSU6JRWK=
LAN-6 NVXH[HFqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV35d5lxUUN3ME2wMlI3OzR6IN88US=> NHnPOplUSU6JRWK=
EW-18 M{DPeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1K5V2lEPTB;MD6yO|AxOSEQvF2= M1m5T3NCVkeHUh?=
LS-1034 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnHjTWM2OD1yLkK3NVMzKM7:TR?= MUjTRW5ITVJ?
EW-11 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mkm4TWM2OD1yLkK4OFMzKM7:TR?= NUjBWolzW0GQR1XS
SNU-C1 M13NNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYPJR|UxRTBwMkmzNVMh|ryP M3PocnNCVkeHUh?=
RS4-11 MnfpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NY\GT2U1UUN3ME2wMlM{PzV6IN88US=> NWfTVlBrW0GQR1XS
ES4 NUnKUHhVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlfsTWM2OD1yLkSxNFM5KM7:TR?= MojBV2FPT0WU
COLO-320-HSR M33LeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXrJR|UxRTBwNEGzOlgh|ryP NULrPJJiW0GQR1XS
NB10 M3PIOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHPZVoRKSzVyPUCuOFU1OzdizszN NFXGc5dUSU6JRWK=
BFTC-905 Mkj1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVTnOpQ6UUN3ME2wMlQ3PzV6IN88US=> MkjUV2FPT0WU
A375 MnTVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYTJR|UxRTBwNEe2NVch|ryP MnjUV2FPT0WU
SJRH30 NUTNZW5[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4fUW2lEPTB;MD61NFgzOiEQvF2= M1zDNXNCVkeHUh?=
NOS-1 Mmr2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkXtTWM2OD1yLkWyNlY4KM7:TR?= MWLTRW5ITVJ?
SIG-M5 MkG1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3LRd2lEPTB;MD61N|U2PyEQvF2= M4T4b3NCVkeHUh?=
DOK NX3Mb5EyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXPJR|UxRTBwNUW2JO69VQ>? MlHnV2FPT0WU
NB69 NXu5[GxvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXnJR|UxRTBwNUiyOVch|ryP NHP1UnBUSU6JRWK=
SK-NEP-1 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWnJR|UxRTBwNkCyN|Yh|ryP M{XGeXNCVkeHUh?=
SK-MM-2 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnPaTWM2OD1yLk[1OFkyKM7:TR?= NITMO3RUSU6JRWK=
NCI-H358 Mk\yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mo\PTWM2OD1yLk[3NFgzKM7:TR?= MUTTRW5ITVJ?
RH-1 NWe3NFVKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2\tSmlEPTB;MD63OFg2QSEQvF2= NULkOpBCW0GQR1XS
NH-12 NGnqNmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoDtTWM2OD1yLke2NFQ3KM7:TR?= MkflV2FPT0WU
TE-12 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoTqTWM2OD1yLke2OFg3KM7:TR?= MVrTRW5ITVJ?
COLO-668 NGnHToFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4DGXmlEPTB;MD64OFY3PiEQvF2= NWXKc4s6W0GQR1XS
PANC-08-13 NIrheFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkPsTWM2OD1yLki2N|c4KM7:TR?= NHjsb2tUSU6JRWK=
HCC2998 NWTpcVZIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4jsUGlEPTB;MD64PFI3OyEQvF2= M3:0fXNCVkeHUh?=
ABC-1 NHrweWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWrGTFJJUUN3ME2wMlkxOzV{IN88US=> NFvXNFVUSU6JRWK=
ES6 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{\4VGlEPTB;MD65NVA3PiEQvF2= NI\sWJRUSU6JRWK=
SNU-387 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NG[2NVFKSzVyPUCuPVk{QTNizszN M1nETnNCVkeHUh?=
CMK NHW2T|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHricJRKSzVyPUCuPVk6OjlizszN M3:wd3NCVkeHUh?=
SJSA-1 M4ewPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlLkTWM2OD1zLkCzOlU{KM7:TR?= NVHCU|NRW0GQR1XS
SIMA NXjLe|dWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1XHcWlEPTB;MT6wOlgzPSEQvF2= MWTTRW5ITVJ?
ES3 NYDNfFlDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVjHZ|ROUUN3ME2xMlEzOjl5IN88US=> MmXSV2FPT0WU
IGROV-1 MkHmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4PW[GlEPTB;MT6xOVQ1PCEQvF2= NUPwZm8zW0GQR1XS
MEL-JUSO M2n4fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVPJR|UxRTFwMUW3OVkh|ryP Mm\1V2FPT0WU
T84 NXTiTXVDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4K1UWlEPTB;MT6yNFkyPCEQvF2= M1z0WHNCVkeHUh?=
CAL-85-1 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHLWdIVKSzVyPUGuNlMyOzhizszN NFnSTm9USU6JRWK=
RD MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWP1O2NRUUN3ME2xMlI3PDV3IN88US=> NETLdZFUSU6JRWK=
TE-8 NV3aVlNrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXXjbm85UUN3ME2xMlMyPDZ{IN88US=> M2\uWXNCVkeHUh?=
L-363 NW\nToZ3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX3JR|UxRTFwM{SyNFgh|ryP MkTnV2FPT0WU
EKVX M3\ofWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVXJR|UxRTFwM{S1Olgh|ryP NVfoTnBlW0GQR1XS
SK-MEL-3 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFjqfZJKSzVyPUGuOFg2PTZizszN M4PCPHNCVkeHUh?=
TGBC24TKB NWe0dYVQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{fQXWlEPTB;MT61NFE6OyEQvF2= NGDzR|hUSU6JRWK=
NCI-H1770 NUL4NJVUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NITGfnJKSzVyPUGuOVEyOTNizszN M{jDRnNCVkeHUh?=
HuH-7 NI\FWWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXvwVng1UUN3ME2xMlYxODl6IN88US=> MlPhV2FPT0WU
HL-60 NI\FUHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUHiPHc6UUN3ME2xMlY3QTJ6IN88US=> NYDCTppGW0GQR1XS
TE-1 NFP6dlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXHJR|UxRTFwN{C5OFUh|ryP MnSyV2FPT0WU
LC-2-ad MoXmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGrXdmNKSzVyPUGuO|M5QDdizszN M2fpOHNCVkeHUh?=
LB647-SCLC NYH6cotxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV[zNldxUUN3ME2xMlc3PTh|IN88US=> M17DSnNCVkeHUh?=
NCI-H2171 M3LiR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUPJR|UxRTFwN{e3NVYh|ryP MoTLV2FPT0WU
SK-PN-DW MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUPJR|UxRTFwOUGyPVgh|ryP MkLLV2FPT0WU
MC-IXC NFO4T3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIPDWGFKSzVyPUGuPVg6QCEQvF2= MVnTRW5ITVJ?
LS-513 NGnsemhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF[0RnFKSzVyPUKuNFU{ODVizszN NWXHdlV[W0GQR1XS
EW-3 NXS2fIlMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MW\JR|UxRTJwMEm4OFQh|ryP NYSxS4RZW0GQR1XS
OPM-2 NFfBRpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{GyNWlEPTB;Mj6xNFIh|ryP NFH4UYJUSU6JRWK=
LP-1 MkXUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUTJR|UxRTJwMkW4NFch|ryP MVrTRW5ITVJ?
LU-134-A MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUn2Uml7UUN3ME2yMlI4PyEQvF2= NFftNm1USU6JRWK=
CP66-MEL MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoC3TWM2OD1{LkK5NFE1KM7:TR?= MWPTRW5ITVJ?
HCC1143 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4\zZWlEPTB;Mj60OVM3QCEQvF2= M2XabHNCVkeHUh?=
LOXIMVI NXezTIpsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV7CZVh4UUN3ME2yMlYxOjFizszN MWfTRW5ITVJ?
TE-10 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2\od2lEPTB;Mj63NFg{QCEQvF2= MlLXV2FPT0WU
NCI-H1882 NX7MOJJXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYjJNGduUUN3ME2yMlc2OjJ5IN88US=> NYjtZZo3W0GQR1XS
CHP-126 MnLuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MU\JR|UxRTJwN{[zNVch|ryP NHrhcWlUSU6JRWK=
NCI-H1623 Mn33S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYrJR|UxRTJwOUKwNlQh|ryP NYjsfXRHW0GQR1XS
GB-1 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV7JR|UxRTJwOUO0NFQh|ryP NEfyNlVUSU6JRWK=
RCC10RGB NXmx[VF5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGfLSnVKSzVyPUKuPVUzQDFizszN MW\TRW5ITVJ?
NCI-H2141 MkfiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVfyb2FwUUN3ME2yMlk3QDl4IN88US=> Mkm2V2FPT0WU
GI-ME-N NUfmUXU{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX7JR|UxRTNwMEC1OlUh|ryP NXLIOIhyW0GQR1XS
NCI-H526 MnL4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWXPO2F2UUN3ME2zMlA1ODh3IN88US=> MV7TRW5ITVJ?
NCI-H747 NEDrNHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnX5TWM2OD1|LkC0PVkzKM7:TR?= NYTPSW9vW0GQR1XS
SNU-423 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYTJR|UxRTNwMkCzNVMh|ryP MV3TRW5ITVJ?
A427 M4f0OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIewNZJKSzVyPUOuNlU3QTlizszN NFPMelZUSU6JRWK=
CAL-12T M3LzPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEjDT2lKSzVyPUOuOFA4OTNizszN MXvTRW5ITVJ?
LU-99A Mof5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUXXSY9YUUN3ME2zMlQ4OTB3IN88US=> MYnTRW5ITVJ?
MS-1 M2PrcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2[4SmlEPTB;Mz61N|QzQSEQvF2= Mnu1V2FPT0WU
SK-LU-1 NFrFdm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3;nbmlEPTB;Mz63OlI6PSEQvF2= NEDTW|VUSU6JRWK=
SW837 M37FOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1HGWmlEPTB;Mz63OlM{OyEQvF2= NH7JNmxUSU6JRWK=
ES8 MoHUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlPsTWM2OD1|LkizPFc4KM7:TR?= MnvnV2FPT0WU
MZ2-MEL Mnu3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{Drd2lEPTB;Mz65NlA5PiEQvF2= NYOyTWdxW0GQR1XS
TGW NF3F[5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVjJR|UxRTRwMEGzNVEh|ryP M{TKUnNCVkeHUh?=
GP5d MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFrHTIFKSzVyPUSuNFU{PjJizszN NG\GUGFUSU6JRWK=
BB49-HNC M1nWTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn:xTWM2OD12LkG1NlE{KM7:TR?= NHXuW5RUSU6JRWK=
NB13 MkGyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHyyWG1KSzVyPUSuNlY5QDdizszN MV;TRW5ITVJ?
NTERA-S-cl-D1 NXHNVZI6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHu3bmhKSzVyPUSuNlg3OTVizszN NG\Oe4lUSU6JRWK=
NCI-H1648 NUfiZ|JJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3vQT2lEPTB;ND6yPVgyQSEQvF2= NFzz[21USU6JRWK=
LCLC-103H NEm4RoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXrJR|UxRTRwM{KxPVUh|ryP MlLQV2FPT0WU
LS-411N M4G2Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHfJcFZKSzVyPUSuOFQ5QDVizszN MYLTRW5ITVJ?
NCI-H1092 NILxVVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2fsWWlEPTB;ND60OVY5PyEQvF2= Ml;jV2FPT0WU
PANC-10-05 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHfkV5pKSzVyPUSuOlk5PCEQvF2= NUTyPWFWW0GQR1XS
DK-MG NFfGemlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVTJR|UxRTRwOEC5N|Mh|ryP NGjTT3BUSU6JRWK=
OVCAR-5 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmrnTWM2OD12LkixNlI3KM7:TR?= MYnTRW5ITVJ?
CAL-39 M2jMU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NI[zPZVKSzVyPUSuPFc3PyEQvF2= MULTRW5ITVJ?
TE-441-T MlLUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXnJR|UxRTRwOUC1N|ch|ryP MVTTRW5ITVJ?
MOLT-16 NEe1bVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIH6ZZBKSzVyPUSuPVUzPTNizszN NU\oe|RWW0GQR1XS
MCF7 M2XK[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{O2WGlEPTB;NT6xOFUyPyEQvF2= MmThV2FPT0WU
CAPAN-1 M{TwZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoftTWM2OD13LkK1O|A4KM7:TR?= NILyUZRUSU6JRWK=
PSN1 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2L0TWlEPTB;NT6yO|I{PSEQvF2= MWjTRW5ITVJ?
NCI-H292 NEXW[WxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYHR[WNHUUN3ME21MlMxODR2IN88US=> NIHrepBUSU6JRWK=
CPC-N MmTTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX;JR|UxRTVwM{m0NVkh|ryP MVfTRW5ITVJ?
DoTc2-4510 NHnmbXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mk[3TWM2OD13LkS1N|cyKM7:TR?= MX3TRW5ITVJ?
LB1047-RCC Ml;YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1HwTGlEPTB;NT61OVk{OyEQvF2= NF;qRVZUSU6JRWK=
MHH-ES-1 M3HySmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mo\ITWM2OD13LkW5PVA4KM7:TR?= NHvTR2RUSU6JRWK=
NMC-G1 MnHuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV;zdFNMUUN3ME21MlcxOjJ5IN88US=> MlTLV2FPT0WU
SW1710 M{\vc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVTjVWZiUUN3ME21Mlc1PzVzIN88US=> MV;TRW5ITVJ?
YAPC NEXUNFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFT0UHhKSzVyPUWuO|YzODFizszN NVfqXHJwW0GQR1XS
22RV1 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NELZbVVKSzVyPUWuPFAxOTlizszN NYrnboI6W0GQR1XS
COLO-679 NYe1W5VCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYmyXXNKUUN3ME21Mlg5QTR6IN88US=> M3y4SXNCVkeHUh?=
TCCSUP M{XvdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYXJR|UxRTVwOUOyOVkh|ryP NI\OfoZUSU6JRWK=
C2BBe1 M2XHXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUDJR|UxRTVwOUO5O{DPxE1? MnzSV2FPT0WU
TE-15 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MonXTWM2OD14LkC2OlA2KM7:TR?= M1rzVXNCVkeHUh?=
SCLC-21H M1nkVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYS2UY9JUUN3ME22MlExQDR|IN88US=> MnXyV2FPT0WU
EoL-1-cell MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2jaT2lEPTB;Nj6xOlU3OyEQvF2= NGDNNmRUSU6JRWK=
NKM-1 MnjDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWT5dIhsUUN3ME22MlE3PzFizszN MUXTRW5ITVJ?
NCI-H1304 NVj4c5JHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUH5dlFKUUN3ME22MlI4PDJ6IN88US=> NWDhNHRMW0GQR1XS
NB6 MmfFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{LIcGlEPTB;Nj6yPVYzOiEQvF2= MnXtV2FPT0WU
NALM-6 NHPI[YRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXPTNY5yUUN3ME22MlM{OjNizszN M2W5cXNCVkeHUh?=
NCI-H522 NV;HR21ST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXT2d3F7UUN3ME22MlM{OzB4IN88US=> Ml3GV2FPT0WU
MV-4-11 M4TOc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWPJT5N2UUN3ME22MlM4ODd7IN88US=> Mn:xV2FPT0WU
LB2241-RCC M2frc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHy0fIlKSzVyPU[uN|g3PjdizszN NVfLSZRDW0GQR1XS
NCI-H1417 NHHOXWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3e2emlEPTB;Nj60NFg1PyEQvF2= MXfTRW5ITVJ?
HT-1197 NF63cJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2Xtd2lEPTB;Nj61O|EzOiEQvF2= MkfxV2FPT0WU
P30-OHK MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVPncHB6UUN3ME22MlYzPzdizszN MXzTRW5ITVJ?
ALL-PO NFL2Vm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYjZeY9YUUN3ME22MlcyQTF4IN88US=> M4HmcHNCVkeHUh?=
OVCAR-4 MoqzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUXJR|UxRTZwN{W0NFUh|ryP MUDTRW5ITVJ?
HCC2157 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYfn[GdiUUN3ME22Mlc4PDd3IN88US=> MVPTRW5ITVJ?
NCI-H838 Mof0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHzSZllKSzVyPU[uPVY1QSEQvF2= NYLHXXFiW0GQR1XS
NCI-H1299 MlTJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3fWbWlEPTB;Nj65O|A6KM7:TR?= MYTTRW5ITVJ?
SW954 NV3T[lY{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{HvPWlEPTB;Nz6yNFA3QCEQvF2= Ml76V2FPT0WU
NCI-H441 NXLoOVN1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MU\JR|UxRTdwM{SwOlUh|ryP MlzWV2FPT0WU
SK-MEL-2 M2rrZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4O4SGlEPTB;Nz60PFM4OyEQvF2= M3HYWHNCVkeHUh?=
KARPAS-45 NEPOSmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml3iTWM2OD15Lk[1PVI6KM7:TR?= MknOV2FPT0WU
CAL-54 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXLET|M2UUN3ME23MlgzQTd5IN88US=> MWXTRW5ITVJ?
KYSE-180 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWm2W4JIUUN3ME23Mlg5QTRzIN88US=> MWTTRW5ITVJ?
NCI-H187 M3;DWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUXJR|UxRTdwOUW5OFch|ryP NIrBSoJUSU6JRWK=
RT-112 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYnIb|ZYUUN3ME24MlA6Pjd5IN88US=> NHjSNldUSU6JRWK=
NCI-H1437 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWnJR|UxRThwMEm3PVUh|ryP M{K4[XNCVkeHUh?=
SNU-449 M4XjVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYHB[Yd[UUN3ME24MlI5Ojd{IN88US=> Moj3V2FPT0WU
HCC1187 NVz4cGs3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYnJR|UxRThwMkmzPVEh|ryP NEW1OJRUSU6JRWK=
NCI-H2030 NWnZfWdTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmHiTWM2OD16LkO3O|E1KM7:TR?= Mo\kV2FPT0WU
HuO-3N1 NF2xVoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkS2TWM2OD16LkO3PFQ1KM7:TR?= NXHofXVrW0GQR1XS
COLO-792 M2D6[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGXBcXlKSzVyPUiuOFE2OjdizszN NHTYTJRUSU6JRWK=
MIA-PaCa-2 M1z4cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV7ubXg6UUN3ME24Mlg2PTB6IN88US=> MmixV2FPT0WU
SK-N-FI NEfvcGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1HafGlEPTB;OT6wOFI2KM7:TR?= M2TiRXNCVkeHUh?=
MMAC-SF NHLpOVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIezW3ZKSzVyPUmuNFk4PTFizszN MmjpV2FPT0WU
NCI-H28 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXzSV445UUN3ME25MlExPDZ7IN88US=> MWPTRW5ITVJ?
ETK-1 NF;HXoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1ns[WlEPTB;OT6yPVk4PCEQvF2= NHT5cZJUSU6JRWK=
NCI-H1993 NWLNPFNrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGfZcpFKSzVyPUmuOFQzPjFizszN NHHLZ3NUSU6JRWK=
no-11 NYTpUYRST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkjNTWM2OD17LkS3NVIh|ryP MnvYV2FPT0WU
ChaGo-K-1 NVPaPXY6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHzHTHNKSzVyPUmuOVE2QDNizszN M3S2ZnNCVkeHUh?=
NCCIT NETKdnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYfJR|UxRTlwNUOxOlkh|ryP MlXNV2FPT0WU
SAS NVS2e3NUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXLJR|UxRTFyLkK0PEDPxE1? Ml;YV2FPT0WU
A673 NXLkcnBST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXzNWVJWUUN3ME2xNE4{PzB2IN88US=> NFrDOVhUSU6JRWK=
NCI-H1522 M{fPbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MU\JR|UxRTFyLkO3NFch|ryP MVnTRW5ITVJ?
NCI-H810 NXTF[YY{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mm\CTWM2OD1zMD6zPVA4KM7:TR?= NX7UR5NMW0GQR1XS
IST-MES1 M2TRe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NY\1R2hLUUN3ME2xNE41PTZ2IN88US=> M{TZZnNCVkeHUh?=
GR-ST NX\xbXJKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXTVUpRxUUN3ME2xNE42ODJ2IN88US=> MXTTRW5ITVJ?
SUP-T1 NFjlfGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MULJR|UxRTFyLkezNVch|ryP NYG2TYFQW0GQR1XS
NB5 Ml\0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGrEVXZKSzVyPUGwMlkxOjJizszN MVPTRW5ITVJ?
MZ1-PC NFz6dlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlrUTWM2OD1zMD65OVcyKM7:TR?= M{LnW3NCVkeHUh?=
SK-CO-1 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mlr1TWM2OD1zMD65PVMyKM7:TR?= MVPTRW5ITVJ?
Capan-2 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{PBXGlEPTB;MUGuN|E6QCEQvF2= M1zxPHNCVkeHUh?=
697 NV3DcFByT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWDJR|UxRTFzLk[3OVch|ryP NXzkW5RGW0GQR1XS
REH NUnTRm8xT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUTlXFNHUUN3ME2xNU44PDVzIN88US=> NEPL[49USU6JRWK=
GI-1 NEXzepVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1TBfGlEPTB;MUGuPFYyPSEQvF2= M1PRUXNCVkeHUh?=
BB65-RCC MmrXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mm[5TWM2OD1zMj6wPVE3KM7:TR?= M13tcHNCVkeHUh?=
NCI-H1651 NX3WbYFKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEiwNHhKSzVyPUGyMlI1PzhizszN M3nC[HNCVkeHUh?=
NCI-H1618 NVXhT3lsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmmzTWM2OD1zMj6zPVc3KM7:TR?= NWH6T5NYW0GQR1XS
NCI-H2081 MnnTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{jrVWlEPTB;MUKuOlE1OSEQvF2= Ml[0V2FPT0WU
GCIY M1qxV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmTkTWM2OD1zMj63NlE{KM7:TR?= NVjkOFE1W0GQR1XS
NY NF21dVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFPPSHZKSzVyPUGzMlA3PDNizszN NXPYcVN{W0GQR1XS
PANC-03-27 NF73dVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUm5Rm46UUN3ME2xN{4xQDB5IN88US=> M3m5dnNCVkeHUh?=
BHY M3XlNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHfSTZRKSzVyPUGzMlIyOjFizszN MkXnV2FPT0WU
SK-OV-3 NX3DdGtOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2P1UmlEPTB;MUOuN|c3OyEQvF2= NGfPRpJUSU6JRWK=
5637 M4exXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYTwT|hPUUN3ME2xN{44PzV7IN88US=> Mmm2V2FPT0WU
LC-1F M3nhZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4XYOGlEPTB;MUSuNFM2PiEQvF2= NHHKNHNUSU6JRWK=
SNB75 NFLD[3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlSzTWM2OD1zND6wN|g{KM7:TR?= NGjX[5lUSU6JRWK=
CHP-212 NYXxPVFYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHzZb4NKSzVyPUG0MlA1PjRizszN MWfTRW5ITVJ?
HT-1376 MljWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2DITWlEPTB;MUSuNVEzPiEQvF2= MV\TRW5ITVJ?
MONO-MAC-6 M3jafWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYXJR|UxRTF2LkG1NFIh|ryP Mn7oV2FPT0WU
CA46 NHLkcIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoK0TWM2OD1zND6xPFI4KM7:TR?= MUXTRW5ITVJ?
SCC-15 M4XLXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHTZZ4NKSzVyPUG0MlU2QDNizszN NGTRO21USU6JRWK=
ATN-1 MoG3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnTrTWM2OD1zND62OlI4KM7:TR?= MVTTRW5ITVJ?
NCI-H2405 M4L3e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHy1OXRKSzVyPUG0MlgyPTdizszN M{nEe3NCVkeHUh?=
NCI-H716 M1XjTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWnJR|UxRTF2Lki0PVMh|ryP M1TweHNCVkeHUh?=
SW620 NXnESVhYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4rBXWlEPTB;MUSuPVAyPCEQvF2= NV3G[IFtW0GQR1XS
NCI-H226 NWLQV2lOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3vleWlEPTB;MUSuPVA5PSEQvF2= NV;LSXNxW0GQR1XS
SW962 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYm3UHVWUUN3ME2xOE46PDN{IN88US=> MlnjV2FPT0WU
KYSE-150 M4nCNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWDJR|UxRTF2Lkm1OUDPxE1? Ml3vV2FPT0WU
OCUB-M NXPQVo9wT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGn5OXdKSzVyPUG0Mlk5QDNizszN NXKySlZ4W0GQR1XS
ES7 M{PXWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnuwTWM2OD1zNT6wPVg1KM7:TR?= NVmxe5RKW0GQR1XS
SW1463 MoSzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2\FSGlEPTB;MUWuOFIzOyEQvF2= MY\TRW5ITVJ?
CAKI-1 NVvGVo9TT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3zWTWlEPTB;MUWuOVM1PiEQvF2= MXnTRW5ITVJ?
MKN28 M1f3dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWO2ZVNtUUN3ME2xOU42PDd7IN88US=> MWrTRW5ITVJ?
SW13 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUHJR|UxRTF3Lk[xPEDPxE1? NF;hOpJUSU6JRWK=
A3-KAW MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmP5TWM2OD1zNT65Olk4KM7:TR?= M3vWOHNCVkeHUh?=
LU-65 NEjDdG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{PRWGlEPTB;MUWuPVc3QCEQvF2= NVrIbW5SW0GQR1XS
Calu-1 NFz3V4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MofQTWM2OD1zNj6wN|Y5KM7:TR?= Ml60V2FPT0WU
ST486 NV\CfZhET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWLJR|UxRTF4LkC0N|Eh|ryP MlPxV2FPT0WU
BB30-HNC Mk\6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXfJR|UxRTF4LkGyOFYh|ryP NHTzenFUSU6JRWK=
EGI-1 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYLJR|UxRTF4LkS0OkDPxE1? NUjD[mFHW0GQR1XS
SH-4 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXuzXXF{UUN3ME2xOk41PzNzIN88US=> MXXTRW5ITVJ?
MN-60 Mlu1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX\JR|UxRTF5LkKyPVch|ryP MWjTRW5ITVJ?
MPP-89 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFH0UWZKSzVyPUG3MlI1PTlizszN M1LieHNCVkeHUh?=
A2780 MkLKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2P2RmlEPTB;MUeuOFE{QSEQvF2= MXfTRW5ITVJ?
Daoy NGq0R5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYXZW4lRUUN3ME2xO{41Pjl3IN88US=> Mn30V2FPT0WU
NCI-H2126 NH3FV|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWTJR|UxRTF5LkS3O|Eh|ryP MWHTRW5ITVJ?
NCI-H1563 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3\UcGlEPTB;MUeuOFkyPyEQvF2= NF7uVmhUSU6JRWK=
8-MG-BA M3zZXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF7Me|VKSzVyPUG3MlY3PDhizszN MkXwV2FPT0WU
786-0 NXzWUYN4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mkn6TWM2OD1zNz64N|U{KM7:TR?= MmH5V2FPT0WU
AM-38 NFXW[oFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWjNSlhlUUN3ME2xO{46OzB4IN88US=> MXzTRW5ITVJ?
COLO-824 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mk\4TWM2OD1zOD60OFM3KM7:TR?= M{XYSXNCVkeHUh?=
SK-MEL-30 M{TjOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVLJZ2Y4UUN3ME2xPE42ODh{IN88US=> M1XTU3NCVkeHUh?=
CESS M2fxemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mnn6TWM2OD1zOD63OlA6KM7:TR?= NVL0UVl3W0GQR1XS
BL-70 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHjlNnlKSzVyPUG4MlgyPTZizszN M362Z3NCVkeHUh?=
NCI-H2170 MnjwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXLJR|UxRTF6LkmxO|kh|ryP MXXTRW5ITVJ?
HT-3 M324emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlyyTWM2OD1zOD65PFMh|ryP NUTYdphLW0GQR1XS
BOKU NIO3c|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFTESJRKSzVyPUG5MlA{QDFizszN NX;4SWhRW0GQR1XS
HPAF-II MnjQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYPJR|UxRTF7LkOwNVUh|ryP NIfBNWJUSU6JRWK=
KGN NHW5VmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1TIcmlEPTB;MUmuOFc3PSEQvF2= NXTwbmFkW0GQR1XS
MC-CAR MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV\JR|UxRTF7Lk[zNVMh|ryP NXLIcYZ7W0GQR1XS
BHT-101 M1\X[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUXJR|UxRTF7Lke3O{DPxE1? M4Pq[3NCVkeHUh?=
SW1783 NHLa[YRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWL4O|k{UUN3ME2xPU44QDB4IN88US=> MXrTRW5ITVJ?
KP-N-YN M{XXc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGf3RnVKSzVyPUKwMlAzPjJizszN NHfSVmFUSU6JRWK=
LU-165 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{DDTGlEPTB;MkCuOVU4OSEQvF2= NVXTfHdQW0GQR1XS
GOTO M1HFOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUHJR|UxRTJyLk[0OVEh|ryP NVHQS|ZNW0GQR1XS
EFM-19 MkGxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYrJR|UxRTJzLkC3NVYh|ryP M3X3e3NCVkeHUh?=
CTV-1 NX;IU|dkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUXJR|UxRTJzLkGwOVQh|ryP MV;TRW5ITVJ?
HEL MoPYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXHJR|UxRTJzLkSyNVYh|ryP Ml[zV2FPT0WU
SNU-C2B MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYLJR|UxRTJzLkSyOkDPxE1? MWrTRW5ITVJ?
ECC4 M3PRbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1nyU2lEPTB;MkGuO|A4KM7:TR?= NInVPZZUSU6JRWK=
NEC8 NX3ZcWVDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUjJR|UxRTJzLkizOlgh|ryP MV3TRW5ITVJ?
KMOE-2 NUKwWnc2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUjVNWdzUUN3ME2yNU45QTJzIN88US=> M1fqWHNCVkeHUh?=
NCI-H524 MmTNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1L4fmlEPTB;MkKuNFgxQCEQvF2= NWDid5VjW0GQR1XS
WSU-NHL MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEfZW45KSzVyPUKyMlE2PzdizszN MomzV2FPT0WU
SF126 M1XzSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlXETWM2OD1{Mj6yOFY6KM7:TR?= MWfTRW5ITVJ?
HOP-92 MmfjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1\zeGlEPTB;MkKuN|E3PyEQvF2= NX3CN3hlW0GQR1XS
CTB-1 Ml3lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWfJR|UxRTJ{LkS2O|ch|ryP MmP4V2FPT0WU
KYSE-270 NUe1ZotQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXK0d5VXUUN3ME2yNk46OzV5IN88US=> MYfTRW5ITVJ?
SK-MEL-24 NHqzNnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX7JR|UxRTJ|LkG4O{DPxE1? NXLtT4s6W0GQR1XS
Calu-3 M4POXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXrJR|UxRTJ|LkKxNlgh|ryP MUHTRW5ITVJ?
GAMG MoLTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXzJR|UxRTJ|LkKzOlch|ryP Moq4V2FPT0WU
SW1573 NYG4RlRuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYXJR|UxRTJ|Lke0NVUh|ryP M4nOcnNCVkeHUh?=
MHH-NB-11 NUD5foFET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NI\odYpKSzVyPUK0MlAyQTRizszN NG\LcmRUSU6JRWK=
TK10 M4DiVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3PRT2lEPTB;MkSuOVAyOyEQvF2= M{\5WXNCVkeHUh?=
LB373-MEL-D MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NELuRnBKSzVyPUK0MlYxPjRizszN M4S4e3NCVkeHUh?=
KALS-1 NVXIbG9CT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2LGU2lEPTB;MkSuO|MzPyEQvF2= MlO3V2FPT0WU
HUTU-80 M130Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXG3U|ZqUUN3ME2yOU45ODN{IN88US=> NGPGeohUSU6JRWK=
HuP-T3 NX3Cbm5FT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFzndlNKSzVyPUK2MlE3PzRizszN MlvGV2FPT0WU
OE19 MnjCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUXIfmhmUUN3ME2yOk4zOTV|IN88US=> NYXyRZdmW0GQR1XS
J82 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml22TWM2OD1{Nj6yOFcyKM7:TR?= MYjTRW5ITVJ?
DU-4475 MoCwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4fzPGlEPTB;Mk[uN|gyQSEQvF2= M{LIRnNCVkeHUh?=
DMS-53 M2n3[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYrIfm9QUUN3ME2yOk42OTN6IN88US=> Ml3RV2FPT0WU
COLO-741 MlX5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXjJR|UxRTJ4LkizOFQh|ryP M2XsWHNCVkeHUh?=
SW48 NUD1SooxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1jxTGlEPTB;Mk[uPFgzKM7:TR?= NHvyeVVUSU6JRWK=
IGR-1 NEPZNlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmTQTWM2OD1{Nj65N|M1KM7:TR?= M4Lac3NCVkeHUh?=
639-V NHHPU4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUj6PZZbUUN3ME2yO{4xOjR3IN88US=> NYTFS|RJW0GQR1XS
LK-2 NXHaWFlMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkjNTWM2OD1{Nz60NVQyKM7:TR?= NInCN4hUSU6JRWK=
NCI-H2347 Mk\ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3rtemlEPTB;MkeuPVY6QSEQvF2= NUj0V|BYW0GQR1XS
NCI-H2228 M{Tqemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1jXZ2lEPTB;MkiuNFkxPSEQvF2= MnnTV2FPT0WU
LS-123 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2f5XGlEPTB;MkiuNVI3OiEQvF2= NEi2XIVUSU6JRWK=
U031 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXjJR|UxRTJ6LkK1NkDPxE1? M4r1dXNCVkeHUh?=
NCI-H1792 NHzoenRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnfQTWM2OD1{OD60O|IyKM7:TR?= NU\3b45{W0GQR1XS
NCI-H2087 M1fMVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mm\ETWM2OD1{OD63OVUzKM7:TR?= M2XYVXNCVkeHUh?=
NCI-H2342 MmmxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkK3TWM2OD1{OT61NlA5KM7:TR?= NGDrZpFUSU6JRWK=
SW626 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnH1TWM2OD1{OT63OVYh|ryP NULvVZFqW0GQR1XS
LB2518-MEL NHzRflZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHrk[m5KSzVyPUK5MlgyPSEQvF2= NVHGeHNqW0GQR1XS
RXF393 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWDJR|UxRTNyLkC5OVIh|ryP NHi1[pNUSU6JRWK=
LC4-1 MkexS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUTVTmszUUN3ME2zNE4{ODl{IN88US=> NYr2[ZZXW0GQR1XS
NCI-H1694 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXHJR|UxRTNyLk[2NlQh|ryP Mlm1V2FPT0WU
K5 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWnX[WZ2UUN3ME2zNE46PzB{IN88US=> M4GzO3NCVkeHUh?=
HDLM-2 M2O0U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmTmTWM2OD1|MD65O|I2KM7:TR?= NF7Eb5BUSU6JRWK=
BCPAP M4nYfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFjLXm5KSzVyPUOxMlg{PzlizszN NEmye|FUSU6JRWK=
BC-3 NF3TbZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWTJR|UxRTN{LkG0NFMh|ryP M33aU3NCVkeHUh?=
LB996-RCC Mn\3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX;uRnM4UUN3ME2zNk4zOzV6IN88US=> NHzFUFhUSU6JRWK=
NCI-H2009 NIfNOZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGnwVHhKSzVyPUOyMlQ6QDFizszN MYDTRW5ITVJ?
HTC-C3 NXHPZ2tKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmH5TWM2OD1|Mz63OVE6KM7:TR?= MlnrV2FPT0WU
LAMA-84 NHf4ZldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWTJR|UxRTN2LkS0NFch|ryP M3Ph[HNCVkeHUh?=
CCRF-CEM M{\vO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXLJR|UxRTN2LkW3NVUh|ryP NYT4e4pIW0GQR1XS
AN3-CA M{f4RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVj0dIRTUUN3ME2zOU4xPTZ6IN88US=> MXfTRW5ITVJ?
NCI-H1734 NUnKRm9ST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWnJR|UxRTN3LkK1OlEh|ryP NXrCTmJlW0GQR1XS
Ca-Ski NUjYUpNQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIXTd5lKSzVyPUO1MlQyODFizszN MWrTRW5ITVJ?
U-266 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mo\rTWM2OD1|NT62NVE1KM7:TR?= MlPWV2FPT0WU
SBC-5 M3nHN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1niemlEPTB;M{WuO|c5OSEQvF2= Mof6V2FPT0WU
GT3TKB MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVrvcGJ2UUN3ME2zO{4yOTVizszN NFTWNpJUSU6JRWK=
MDA-MB-175-VII NE\0NVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{D5[mlEPTB;M{euNlI1QCEQvF2= NULuZoF6W0GQR1XS
PFSK-1 NGTxNJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{[xTGlEPTB;M{euNlQ{PSEQvF2= MXjTRW5ITVJ?
IMR-5 NVnKcmpHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWLZRmtRUUN3ME2zO{4zPDh5IN88US=> M1\JN3NCVkeHUh?=
Daudi M2jw[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXHJR|UxRTN5LkO1PVch|ryP NXLCSJBuW0GQR1XS
A498 M1vucmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2DP[mlEPTB;M{euO|IyQCEQvF2= NFq5cVBUSU6JRWK=
SCC-4 NHLiVGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1LNV2lEPTB;M{euO|g1OyEQvF2= M1[yZnNCVkeHUh?=
COLO-680N MlPiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYDJR|UxRTN6LkK4PFUh|ryP MX\TRW5ITVJ?
SK-MES-1 MorRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX7sWVlIUUN3ME2zPE4{OjF3IN88US=> M13Ne3NCVkeHUh?=
SR M{njSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mof6TWM2OD1|OD61OFk2KM7:TR?= M3PqcHNCVkeHUh?=
LNCaP-Clone-FGC NGK1VmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkWzTWM2OD1|OD61OlM4KM7:TR?= MVrTRW5ITVJ?
SK-HEP-1 NYTKSGNlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYnJR|UxRTN6Lke4NlIh|ryP NF3ycldUSU6JRWK=
BPH-1 NHLySY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mkm0TWM2OD1|OD64N|I6KM7:TR?= MU\TRW5ITVJ?
NCI-H1755 Mo\oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1Tsb2lEPTB;M{muOVgyPyEQvF2= M4nRU3NCVkeHUh?=
LXF-289 NHHZT|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4\v[mlEPTB;M{muPFA5PCEQvF2= NWLIPHNtW0GQR1XS
SW1088 NY\TTWo6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWHJR|UxRTRyLkKxNFch|ryP MWnTRW5ITVJ?
MOLT-4 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MorXTWM2OD12MD6yPVAyKM7:TR?= MlHQV2FPT0WU
AsPC-1 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVnJR|UxRTRyLkS1PFMh|ryP NHi0b|BUSU6JRWK=
HOP-62 NGq2WI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3fYeWlEPTB;NECuOlU3QCEQvF2= NX3FWZF{W0GQR1XS
A172 Ml7hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUDYZ5h{UUN3ME20NE45PTFzIN88US=> NF3veHpUSU6JRWK=
SN12C MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{DZd2lEPTB;NECuPVM5PSEQvF2= M4DpWHNCVkeHUh?=
MDA-MB-231 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoK0TWM2OD12MD65PFk5KM7:TR?= NVW3d|V4W0GQR1XS
RPMI-2650 M{TZZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV3JPGUzUUN3ME20NU4yPTl|IN88US=> NF7xeHNUSU6JRWK=
KYSE-140 NYjldohxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXfGN4xiUUN3ME20NU45OTJ|IN88US=> NX3ze3B1W0GQR1XS
KINGS-1 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmfBTWM2OD12Mj60Olk4KM7:TR?= NGLqPHZUSU6JRWK=
HSC-3 NXHYcodQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXnJR|UxRTR{Lk[2OlEh|ryP MnnsV2FPT0WU
PC-14 M3zDPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmLETWM2OD12Mz6xPFgzKM7:TR?= NF;ZOG5USU6JRWK=
COR-L105 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mo\HTWM2OD12Mz62OVAzKM7:TR?= MUfTRW5ITVJ?
BE-13 M1XkcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUXuS3hUUUN3ME20OE4zOzdzIN88US=> M4TTVXNCVkeHUh?=
NCI-H661 NGXmR21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFvYfo1KSzVyPUS0MlI6PThizszN NXfvdZBFW0GQR1XS
IST-MEL1 M1fRZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIm0fXhKSzVyPUS0MlM2QTlizszN MmT2V2FPT0WU
HCC1806 NEXJdoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHLJO5dKSzVyPUS0MlU5PzNizszN NWXNUlVGW0GQR1XS
COLO-800 M4X1emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3vvRWlEPTB;NESuPFQ2OyEQvF2= MnH6V2FPT0WU
IST-SL2 M{iyRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHHWZpVKSzVyPUS1MlEzPDdizszN NHPa[oJUSU6JRWK=
8305C NHG2TI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUPJR|UxRTR3LkOwPUDPxE1? NHPke4FUSU6JRWK=
UACC-62 M1;6cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUXEOIlxUUN3ME20Ok4zQDd3IN88US=> NIHK[ZRUSU6JRWK=
COR-L23 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYTJR|UxRTR5LkG5PUDPxE1? M1T2SnNCVkeHUh?=
EFE-184 NVTvflFlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVLJR|UxRTR5LkO4PEDPxE1? NVW3cGZJW0GQR1XS
DMS-114 M2H1Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX3JR|UxRTR5LkSxOFkh|ryP M2Sy[nNCVkeHUh?=
KYSE-520 MmLYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3PUemlEPTB;NEiuOVMyPSEQvF2= MYLTRW5ITVJ?
SNG-M MmfnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2\wR2lEPTB;NEmuOFM1KM7:TR?= MYLTRW5ITVJ?
A2058 NVKwcJFMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUfJR|UxRTR7LkS4PFUh|ryP NVzlc4MzW0GQR1XS

... Click to View More Cell Line Experimental Data

In vivo OSI-906 inhibits tumor growth in an IGF-1R-driven xenograft mouse model, with 100% TGI and 55% regression at a dose of 75 mg/kg and 60% TGI and no regression at a dose of 25 mg/kg. OSI-906 administration induces different elimination half-lives of itself in dog, rat and mice, the elimination half-lives are 1.18 hours, 2.64 hours and 2.14 hours, respectively. OSI-906 administration at different single dose once-daily in femal Sprague-Dawley rat and femal CD-1 mouse reveal that the Vmax is not dose-proportional to OSI-906 dose. OSI-906 elevates the blood glucose levels at a dose of 25 mg/kg after 12 days administration. OSI-906 administration at a single dose of 75 mg/kg in IGF-1R-driven full-length human IGF-1R (LISN) xenograft mouse model achieve maximal inhibition of IGF-1R phosphorylation (80%) between 4 and 24 hours with plasma drug concentrations of 26.6-4.77 μM. [1] OSI-906 administered as a single dose of at 60 mg/kg in NCI-H292 xenografts mice inhibits uptake of glucose at 2, 4, and 24 hours post-treatment in vivo. OSI-906 inhibits the growth of tumors in NCI-H292 xenograft mouse model. [2]

Protocol

Kinase Assay:[1]
+ Expand

Protein kinase biochemical assays:

Protein kinase assays are either performed in-house by ELISA-based assay methods (IGF-1R, IR, EGFR and KDR) or at Upstate Inc. by a radiometric method with ATP at 100 µM concentration. In-house ELISA assays use poly(Glu:Tyr) as the substrate bound to the surface of 96-well assay plates and phosphorylation is detected using an antiphosphotyrosine antibody conjugated to horseradish peroxidase. The bound antibody is quantified using ABTS as the peroxidase substrate by measuring absorbance at 405 / 490 nm. All assays use purified recombinant kinase catalytic domains. Recombinant enzymes of human IGF-1R or EGFR are expressed as an NH2-terminal glutathione S-transferase fusion protein in insect cells and are purified in house. IC50 values are determined from the sigmoidal dose–response plot of percent inhibition versus log10 compound concentration. A minimum of three measurements, performed in duplicate, are carried out with in-house assays unless otherwise indicated. OSI-906 at a concentration of 1 µM is profiled versus a panel of kinases using the ProfilerProTM Kinase Selectivity Assay Kit.
Cell Research:[1]
+ Expand
  • Cell lines: MCF7, NCI-H292, Colo-205, HT29, H358, H1703, BxPC3, A673, SW620, DU4475, HepG2 and Hepa-1, RKO 3T3/hulGF-IR and H292 cells
  • Concentrations: 0.02-0.8 μM
  • Incubation Time: 3 days
  • Method: For assays of cell proliferation, cells are seeded into 96-well plates in appropriate media containing FCS 10% and incubated for 3 days in the presence of OSI-906 at various concentrations. Inhibition of cell growth is determined by luminescent quantitation of intracellular ATP content using CellTiterGlo. Data is presented as a fraction of maximal proliferation, calculated by dividing the cellular density in the presence of varying concentrations of OSI-906 by the cellular density of control cells treated with vehicle (DMSO) only.
    (Only for Reference)
Animal Research:[1]
+ Expand
  • Animal Models: IGF-1R-driven full-length human IGF-1R (LISN) xenograft mouse model
  • Formulation: 25 mM tartaric acid
  • Dosages: 25 mg / kg and 75 mg / kg
  • Administration: Orally administrated at once-daily oral dose for 14 days
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 84 mg/mL (199.29 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order:
30% PEG 400+0.5% Tween 80+5% Propylene glycol
For best results, use promptly after mixing.
30mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 421.49
Formula

C26H23N5O

CAS No. 867160-71-2
Storage powder
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02057380 Completed Advanced Solid Tumors Astellas Pharma Global Development, Inc.|Astellas Pharma Inc April 2014 Phase 2
NCT02546544 Active, not recruiting Relapsed Ewing Sarcoma|Refractory Ewing Sarcoma University of Oxford|European Organisation for Research and Treatment of Cancer - EORTC|European Commission|Astellas Pharma Inc|Oxford University Hospitals NHS Trust March 2014 Phase 2
NCT01427205 Withdrawn Head and Neck Cancer M.D. Anderson Cancer Center|OSI Pharmaceuticals June 2013 Phase 2
NCT01567384 Withdrawn Cancer|Neoplasms|Tumors Emory University|OSI Pharmaceuticals May 2012 Phase 1
NCT01560260 Completed Carney Complex|Chondrosarcoma|Gastrointestinal Stromal Tumor|Paraganglioma National Cancer Institute (NCI) March 2012 Phase 2
NCT01533246 Completed Adenocarcinoma of the Prostate|Hormone-resistant Prostate Cancer|Recurrent Prostate Cancer|Stage IV Prostate Cancer National Cancer Institute (NCI) February 2012 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    Does the inhibitor dissolve in the vehicle (30% PEG400/0.5%Tween 80/5% propylene glycol) or is it a suspension?

  • Answer:

    OSI-906 in 30% PEG400/0.5%Tween 80/5% propylene glycol is a suspension.

IGF-1R Signaling Pathway Map

IGF-1R Inhibitors with Unique Features

Related IGF-1R Products

Tags: buy Linsitinib (OSI-906) | Linsitinib (OSI-906) supplier | purchase Linsitinib (OSI-906) | Linsitinib (OSI-906) cost | Linsitinib (OSI-906) manufacturer | order Linsitinib (OSI-906) | Linsitinib (OSI-906) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID